Compare TREX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREX | DNLI |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 1998 | 2017 |
| Metric | TREX | DNLI |
|---|---|---|
| Price | $38.93 | $18.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | ★ $49.53 | $34.33 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $1,174,267,000.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | $6.24 | $408.85 |
| P/E Ratio | $22.14 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $29.77 | $12.58 |
| 52 Week High | $68.78 | $23.77 |
| Indicator | TREX | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 39.79 |
| Support Level | $38.92 | $18.42 |
| Resistance Level | $44.84 | $18.70 |
| Average True Range (ATR) | 1.39 | 0.91 |
| MACD | -0.30 | -0.17 |
| Stochastic Oscillator | 8.76 | 6.69 |
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.